slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 22,051-22,080
Pages 885
Rows per page 30
Arc
22,051-22,080 of 26,550
28
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
29
The title appears cut off at the bottom of the slide.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
30
The slide features a 3D molecular visualization of the inhibitor.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
31
The slide outlines a standard clinical trial progression from dose escalation to expansion, with a focus on establishing RP2D and evaluating ORR.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organ systems.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
33
Includes a biological pathway diagram and a honeycomb-style indication map.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
34
The slide uses a three-column layout to define the target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
35
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
37
The main chart is a waterfall plot showing drug response scores across many samples. The right side details translational findings and a combination testing framework.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
38
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across different drug combinations and patient samples.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
39
Uses a Venn diagram to illustrate overlap between peripheral blood and tumour gene expression data.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
40
The slide features a 3D molecular visualization.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
41
The slide uses a bar chart to demonstrate efficacy at lower doses compared to a failed large pharma drug.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
42
The slide uses a heatmap-style table to visualize performance metrics, highlighting the competitive advantage of the company's lead asset.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
43
The slide outlines a workflow from experimental data collection to AI-driven design and final compound nomination.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
44
The background features a 3D molecular visualization, likely representing the LSD1 protein or the drug binding to it.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
45
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
46
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
47
Includes two scientific citations for the mechanism and brain penetration.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
48
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
49
The slide uses a color-coded heatmap to visualize performance against a Target Product Profile (TPP).Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
50
The slide uses a linear process flow to explain a complex computational chemistry workflow.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
51
The chart uses a Pareto front to illustrate the trade-off between CNS score and Potency, highlighting that the 'best' molecules are not always the most information-rich.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
52
Includes statistical significance markers (*) on the tumour volume chart.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
53
The slide uses two distinct chart types (dot plot and line chart) to demonstrate safety profiles.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
54
The chart shows tumour volume over time for various dosing regimens compared to a vehicle control.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
55
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
56
The slide uses a split-layout to contrast current operational status with overall program value proposition.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
57
The slide uses a stylized molecular visualization as a background element.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit